|Day Low/High||36.36 / 36.68|
|52 Wk Low/High||33.97 / 46.47|
Pfizer Inc. (NYSE: PFE) announced today complete results from a Phase 3, 12-week, pivotal study (JADE MONO-1) in patients aged 12 and older with moderate to severe atopic dermatitis (AD).
Akcea shares soar after the company announces a licensing agreement with Pfizer for its treatment for people with certain cardiovascular and metabolic diseases.
Stocks finish higher after falling earlier in the session following a weak reading on U.S. services sector activity.
Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI ® (encorafenib), MEKTOVI ® (binimetinib), and cetuximab (BRAFTOVI Triplet), in patients with advanced...
Pfizer shares edged higher Friday after the company posted promising results from trials of a drug it's developing to treat patients with moderate-to-severe eczema.
Pfizer Inc. and LabCentral announced that Pfizer has selected Neutrolis and Mediar Therapeutics are the winners of this year's Pfizer Golden Ticket Program.
Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc.
Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate...
The Board of Directors of Pfizer Inc. today declared a 36-cent fourth-quarter 2019 dividend on the company's common stock, payable December 2, 2019, to holders of the Common Stock of record at the close of business on November 8, 2019.
Pfizer Inc. (NYSE: PFE) today announced the presentation of four IBRANCE ® (palbociclib) real-world analyses.
Analyst Bruce Jackson likes the prospects for the producer of a DNA-based colon-cancer-screening test for use at home.
Jim Cramer's breaking down the ticker tape for investors.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.
Pfizer Inc. (NYSE: PFE) announced today positive preliminary results following administration of three doses in a four-dose series for a Proof-of-Concept Phase 2 study (B7471003) to assess safety and immunogenicity of its 20-valent pneumococcal conjugate...
Mark Hulbert takes a look at the stocks most favored by the top-performing newsletters.
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D'Amelio, Chief Financial Officer and Executive Vice President, Global Supply and Business Operations, at the Morgan Stanley 17 th Annual Global...
Stocks finish higher as energy stocks rise on the back of higher oil prices.
Stocks finish down as recession worries again emerge and as investors monitor U.S. and China trade negotiations.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Jim Cramer takes a look at Union Pacific, Pfizer, Merck, AbbVie, Teva Pharmaceuticals, ABM Industries, Schlumberger and more.
XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.
Pfizer announced today an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina.
There has been an EpiPen shortage in the U.S., Europe and Canada, thanks to manufacturing delays at Pfizer.
A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #20 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, PFE claims the #299 spot.
The company announces that rivipansel, which was developed in partnership with Pfizer, didn't meet primary or secondary endpoints.
Pfizer Inc. (NYSE:PFE) announced today that the Phase 3 R ivipansel (GMI-1070): E valuating S afety, E fficacy and T ime to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints.
Pfizer Inc. (NYSE: PFE) today announced the closing of its joint venture with GlaxoSmithKline plc (NYSE: GSK) to combine the parties' respective consumer healthcare businesses to create the world's largest over-the-counter (OTC) business with robust...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.